News of Note—TapImmune’s breast cancer combo, IAVI’s HIV vaccine and more

newspaper
In this week's news of note, the DOD grants $11 million for a TapImmune breast cancer study. (PIxabay)

Here is some other vaccine news of note for the week.

> With a grant of $11 million from the U.S. Department of Defense, investigators will test TapImmune’s breast cancer vaccine, TPIV110, in combination with Roche's Herceptin in a phase 2 study. Release

> The International AIDS Vaccine Initiative has started human testing of a novel HIV vaccine designed to initiate a key first step in the generation of broadly neutralizing antibodies. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The University of Montana won a $10 million, five-year contract from the NIH to develop a new universal flu vaccine. Release

> Valneva nabbed FDA approval for an accelerated, seven-day dosing regimen for Japanese encephalitis vaccine Ixiaro. Release